Citadel Advisors
NKGN

Citadel Advisors’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Citadel Advisors’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-95,438
Closed -$36.1K – 15619
2024
Q3 		$36.1K Buy
+95,438
New +$84.7K ﹤0.01% 12261

Other funds holding NKGN

Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
UOC
University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

Citadel Advisors's NKGN Position: Q4 2024 in Review

Citadel Advisors sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2024, closing a stake of 95,438 shares — an estimated $36.1K sold.

Citadel Advisors first reported a position in NKGN in Q3 2024 and held it in 1 quarter. The position peaked at $36.1K in Q3 2024. 25 funds tracked by Wall St. Rank hold NKGN as of Q4 2024.

  • Citadel Advisors reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 95,438 NKGen Biotech, Inc. Common Stock shares in Q4 2024, an estimated $36.1K.
  • Citadel Advisors first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2024 and held it in 1 quarter.
  • Citadel Advisors's NKGen Biotech, Inc. Common Stock position peaked at $36.1K in Q3 2024.
  • 25 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.